|
Market Closed -
Nasdaq
16:00:00 2026-01-06 EST
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-08 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6.12B 5.79B 5.25B 9.86B 668B 9.92B 69.3B 26.76B 341B 26.13B 25.56B 1,095B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.96B 5.63B 5.11B 9.59B 650B 9.65B 67.44B 26.05B 332B 25.43B 24.88B 1,066B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 93 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 237 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 2025-02-23 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2025-04-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/7/26 | Issuer sale | Chief Financial Officer | 165,651 | 0.6532% | ||
| 1/7/26 | Issuer sale | Director | 35,375 | 0.1395% | ||
| 1/7/26 | Issuer sale | Chief Operating Officer | 241,829 | 0.9537% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 56.2M 53.15M 48.21M 90.53M 6.13B 91.06M 636M 246M 3.13B 240M 235M 10.06B | 1.28M 1.12M 1.06M 962K 1.81M 122M 1.82M 12.7M 4.9M 62.45M 4.79M 4.68M 201M |
| Net income | -22.93M -20.17M -19.07M -17.3M -32.49M -2.2B -32.67M -228M -88.19M -1.12B -86.09M -84.23M -3.61B | -170M -149M -141M -128M -241M -16.3B -242M -1.69B -653M -8.32B -638M -624M -26.73B |
| Net Debt | -30.9M -27.18M -25.7M -23.31M -43.78M -2.97B -44.03M -308M -119M -1.51B -116M -114M -4.86B | -186M -164M -155M -140M -264M -17.88B -265M -1.85B -716M -9.12B -699M -684M -29.32B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
